Skip to content

Study for Perioperative Neurocognitive Disorders After Deep Brain Stimulation Surgery for Parkinson's Disease

Metabonomics Characteristics and Predictive Value for Perioperative Neurocognitive Disorders After Deep Brain Stimulation Surgery for Parkinson's Disease

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04696978
Enrollment
300
Registered
2021-01-06
Start date
2020-08-01
Completion date
2022-12-01
Last updated
2021-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurocognitive Disorders

Brief summary

Perioperative neurocognitive disorders(PND) is common to see in elderly patients. Although PND increases patient mortality as well as hospitalization time, apparent inflammatory factors, and related mechanisms are still unknown. Metabolites could reveal chemical fingerprints left behind by cellular processes, which in turn provide a new aspect to understand the biological process behind. we aim to found the metabolomics can aid the development of diagnostic markers of PND screening, early detection, and further, provide a basis for disease prevention and treatment.

Interventions

None listed

Sponsors

wenbinlu
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

* Parkinson's patients undergoing elective deep brain stimulation * Age ≥55 years * ASA physical statusⅠ-Ⅲ * Elementary school or above

Exclusion criteria

* patients with ASA physical status\>III * patients with systemic immune diseases, hematological diseases (hematological tumors or leukemia), patients after transplantation, malignant tumors * patients with metabolic diseases such as diabetes, ketoacidosis, hyperosmolar syndrome, long-term hypoglycemia,gout * patients who refused to join the study and lost to follow-up

Design outcomes

Primary

MeasureTime frame
the level of metabolomics in patients' blood samplebaseline

Secondary

MeasureTime frame
CAM-ICU scorebaseline

Countries

China

Contacts

Primary Contactwenbin lu
13004162573@163.com13004162573
Backup Contactjinjun bian, M.D
jinjunbicu@163.com13601963321

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026